Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve …
PRESS RELEASES
Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association
NEW YORK and LONDON, June 15, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of …
Akari Therapeutics Receives Notice Related to Delay in 20-F Filing
NEW YORK and LONDON, May 21, 2018 - Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercialization of …
[Read more...] about Akari Therapeutics Receives Notice Related to Delay in 20-F Filing
